RedHill Biopharma has entered into an agreement with Cosmo Pharmaceuticals to further expand manufacturing capacity of a new chemical entity, opaganib (Yeliva), for Covid-19.

Originally developed by US-based Apogee Biotechnology, opaganib is an orally administered, sphingosine kinase-2 (SK2) selective inhibitor with demonstrated dual anti-inflammatory and antiviral activity.

This development is in line with plans to meet prospective demand on obtaining global emergency use authorisations for opaganib.

RedHill Biopharma R&D senior vice-president Reza Fathi said: “Opaganib is designed to act broadly against different viral strains irrespective of mutations in the Spike protein.

“By targeting SK2, a human cell component involved in viral replication irrespective of mutations in the viral Spike protein, opaganib potentially addresses the emergence of new strains.”

Currently, the global Phase II / III study of opaganib in severe Covid-19 pneumonia is progressing with patients enrolled in over 30 sites in various countries.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Last month, RedHill Biopharma received a second unanimous DSMB recommendation to continue the global study of opaganib in patients hospitalised with severe Covid-19 pneumonia.

In a separate development, Valneva commenced production of its inactivated, adjuvanted Covid-19 vaccine candidate, VLA2001, alongside the continuing clinical studies, for optimising the timeline for potential vaccine deliveries.

VLA2001 has inactivated whole virus particles of SARS-CoV-2 with high S-protein density and two adjuvants, alum and CpG 1018.

The Phase I / II clinical study has completed enrolment and should to report initial results in April.

The study, which began in mid-December, enrolled 150 healthy adults aged between 18 and 55 years.

Valneva CEO Thomas Lingelbach said: “Our team in Scotland have done an amazing job to get manufacturing started so quickly.

“I would like to thank the UK Vaccines Taskforce and National Institute for Health Research who have played vital roles in the rapid recruitment and enrollment of the volunteers for the clinical study.”